Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events
Association of inflammatory markers with baseline coronary plaque volumes by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract].
Icosapent ethyl (eicosapentaenoic acid ethyl ester) reduces potentially atherogenic lipid, lipoprotein, apolipoprotein, and inflammatory parameters in high-risk, statin-treated patients with persistent elevated triglycerides and high-sensitivity C-reactive protein: a post hoc subanalysis of the ANCHOR study
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study)
The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease.
Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin
Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid
Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same
Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements
Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products
Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents